61 results about "Cannabielsoin" patented technology

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs. In particular the immunosuppressant drug is a calcineurin inhibitor. More particularly the immunosuppressant drug is tacrolimus. Where the CBD is used in combination with an immunosuppressant drug, caution should be taken. For example, the dose of either the CBD and / or the immunosuppressant drug may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD ap-pears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocan-nabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigero (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

This document provides methods and compositions for neuroprotection. The neuroprotective composition may be or include cannabinol or a derivative thereof. The neuroprotective composition may be used in the treatment of neurodegenerative diseases. It may be used to protect retinal neurons from degeneration in individuals who require it, such as in the treatment of glaucoma.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with Lennox-Gastaut syndrome (LGS) who are deemed to be treatment failures on their existing medication. In particular the use of CBD was found to provide a statistically significant reduction in both drop seizures and total seizure frequency in patients who have tried and failed anti-epileptic drugs (AEDs) or those who were currently taking AEDs but have uncontrolled seizures. Preferably the AEDs which have been shown to be treatment failures are one or more of rufinamide, lamotrigine, topiramate and / or felbamate. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The invention discloses a method for determining the content of forbidden substances in electronic cigarette liquid. The method specifically comprises the following steps: (1) pre-treating a sample; (2) carrying out LC-MS / MS analysis conditions; and (3) determining a standard curve and quantifying. Based on the LC-MS / MS technology, the content of taurine, caffeine, cannabidiol (CBD), tetrahydrocannabinol (THC), vitamin E and vitamin E acetate in the electronic cigarette liquid can be measured at the same time, and therefore the requirements for industry supervision, product quality control and safety evaluation are met.

Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The cannabinoids suitable for use include cannabidiols, cannabinols, and various other naturally occurring and synthetic cannabinoids. The compositions may also further include anti-inflammatory agents, steroids, or terpenoids. In preferred embodiments, the cannabinoids incorporated in the compositions are cannabidiol (CBD) and cannabinol (CBN) while the carriers are selected from the group consisting of Labrasol™, Transcutol™, lecithin, lysolecithin, isopropyl palmitate, and isopropyl myristate.

The invention provides a pharmaceutical formulation containing a particulate porous adsorbent selected from the group of aluminosilicates and their salts, with a neutral or basic pH and a particle size between 50 and 800 μm, onto which a mixture of polyoxyethylene sorbitan monooleate (polysorbate 80) is applied with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC, and D8-THC. This formulation improves the bioavailability and release profile of the cannabinoids.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

Provided are methods of preparing cannabinol from cannabidiol and / or tetrahydrocannabinol and for preparing cannabinol acetate. The methods comprise using catalytic molecular halogen in the presence of an oxidant.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

Disclosed herein are compounds having a structure according to Formula IAlso disclosed are methods for making and using the compounds. The compounds may be useful for treating or preventing a disease or condition in a subject, including a neurodegenerative disease or condition, a metabolic disorder, a traumatic brain injury, or cancer.

Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.

The invention discloses a method for rapidly detecting ten cannabinoids in industrial hemp fresh floral leaves based on an HPLC (High Performance Liquid Chromatography) method. The method comprises the following steps: S1, preparing a mixed standard solution; s2, pretreatment of a fresh industrial cannabis sativa floral leaf sample: liquid nitrogen grinding wall breaking, solvent ultrasonic extraction and low-temperature centrifugation are carried out, and a supernatant is taken for sample preparation; and S3, high performance liquid chromatography determination. The ten cannabinoids disclosed by the invention comprise cannabidiol (CBD), cannabidiol acid (CBDA), hypocannabidiol (CBDV), tetrahydrocannabinol acid (THCA), delta 9-tetrahydrocannabinol (delta 9-THC), delta 8-tetrahydrocannabinol (delta 8-THC), hypocannabinol (THCV), cannabinoid phenol (CBG), cannabinol (CBN) and cannabinocene (CBC). According to the method, the situation that carboxylic acid cannabinoid in fresh floral leaves is prone to decarboxylation conversion in the pretreatment process is fully considered, low-temperature extraction is conducted through liquid nitrogen grinding wall breaking, and it is ensured that carboxylic acid cannabinoid is stable. The detection method disclosed by the invention realizes high-throughput detection of 10 cannabinoids, can rapidly, objectively, accurately and synchronously detect various cannabinoids including carboxylic acid cannabinoids in fresh industrial hemp floral leaves, and has the advantages of short detection time (not exceeding 15 minutes), accurate quantification, reliable result, high efficiency and the like; and a reliable basis can be provided for industrial hemp characteristic variety breeding and scientific harvesting.

There is provided a method of preparing a hemp oil composition, the method comprising the steps of eluting cannabinoid from a dried hemp plant material in a solvent by reflux for a predetermined time to obtain an eluate, filtering the eluate with a series of filters to obtain a filtrate, the solvent in the evaporated filtrate is condensed with a distiller to extract a distillate, and the distillate is purified by fractionation to remove the residual solvent to obtain the cannabis sativa extract. The method further comprises the following steps: carrying out redox reaction on the cannabis sativa extract to completely remove water in the cannabis sativa extract, and preparing CBN (cannabinol) with different percentages according to the time for which the redox reaction is carried out; and mixing the cannabis sativa extract with essential oil or base oil to obtain the cannabis sativa oil composition.

The present invention relates to a solid oral pharmaceutical for Tetrahydrocannabinol (API) or any other Cannabinoid (API) with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Tetrahydrocannabinol and other Cannabinoids can be found in a wide range of indications like pain relief, insomnia, anti- depression and others.

This disclosure provides 8,9-dihydrocannabinoid derivatives, deuterated cannabinoid derivatives, and tritiated cannabinoid derivatives. The disclosure also provides compositions, methods of use, and processes of preparation of the foregoing derivatives.

Compositions containing cannabinoids and kinase inhibitors are useful for the treatment of hepatocellular carcinoma (HCC). Compositions containing cannabinolic acid (CBNA) and sorafenib act synergistically on HepG2 cells, an in vitro liver cancer model, and on ex vivo patient-derived xenograft (PDX) HCC models. The effects of all of the disclosed compositions are superior to sorafenib alone, which is the first- and second-line chemotherapeutic agent for the treatment of HCC.

Provided are compositions containing cannabinol, or a pharmaceutically acceptable salt thereof, and methods of reducing sleep disturbances in a subject, comprising administering the cannabinol composition to the subject. Also provided are methods of treating sleep disorders in a subject, comprising administering the cannabinol composition to the subject.

The present invention relates to a transformed recombinant microorganism capable of producing cannabidiolic acid, and a method for producing cannabidiolic acid by using same. More specifically, the present invention relates to a recombinant microorganism capable of synthesizing cannabidiolic acid from cannabigerolic acid without hemp by using a recombinant vector containing a codon-optimized gene that encodes a cannabidiolic acid synthase.

This disclosure generally relates to gas-phase methods to simultaneously purify and decarboxylate cannabinoids in about two seconds, which are about 100-10,000 times more efficient than conventional purification and decarboxylation strategies. The methods also recover thermolabile cannabinoids such as cannabigerol at significantly higher yields than conventional methods.

The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts thereof or a synthetic intermediate thereof: (I). The compounds may act as medicaments and may be capable of displaying one or more beneficial therapeutic effects, including treating inflammation and targeting IFNg, IL-6, TNF, IL-1B, IL-10, Lox-5, CB2 and / or Lox-15.

Methods for the production of cannabichromene and related cannabinoid compounds are disclosed. The methods include: forming a reaction mixture comprising 3,7-dimethylocta-2,6-dienal, a diamine, and olivetol or a related starting material; and maintaining the reaction mixture under conditions sufficient to form the desired product. Methods of the present disclosure may also include one-pot conversion of cannabichromene-type products to cannabinol-type products.

Provided are methods of preparing cannabinol from cannabidiol and / or tetrahydrocannabinol and for preparing cannabinol acetate. The methods comprise using catalytic molecular halogen in the presence of an oxidant.

This invention provides enzymes and methods for synthesizing cannabinoids specifically and in high yield. [Solution] A method is provided for producing one or more cannabinoids, comprising the step of contacting cannabigerol acid with a cannabinoid synthase ortholog. The cannabinoid synthase ortholog is derived from an organism other than hemp (Cannabis sativa). Also disclosed are recombinant cells of Saccharomyces cerevisiae or Pichia pastoris, which contain nucleic acids encoding the cannabinoid synthase ortholog in their genome. The cannabinoid synthase ortholog is expressed in its active form in the recombinant cells.

A method is provided for the synthesis of (-)-trans-Δ9-tetrahydrocannabivarin (Δ9-THCV) and analogs thereof such that in the reaction product, the molar ratio of the Δ9 isomer to incidentally formed Δ8 isomers is greater than 4:1. Synthesis is carried out by combining a selected cannabinoid reactant, e.g., cannabidivarin (CBDV) or an analog thereof, with an acid in a solvent for the cannabinoid reactant, wherein the acid comprises (i) a Lewis acid having an acid softness index value in the range of -10 ΔG0 f, M n+ to ‑150 ΔG0 f, M n+, (ii) a Brønsted acid having a pKa in the range of -4.0 to +4.0, or (iii) a combination of (i) and (ii), under reaction conditions comprising a reaction temperature in the range of ‑0 °C to 25 °C and a reaction time in the range of 1 hour to 24 hours. The reaction is thereafter quenched with base and the solvent removed, wherein the crude reaction product so provided may be purified, e.g., chromatographically purified. Also provided is a method for synthesizing Δ9-THCV that further includes synthesis of the cannabinoid reactant. The invention additionally provides novel cannabinoid compositions that may be synthesized using the aforementioned methodology.

Hexahydrocannabinol (HHC), hexahydrocannabidiol (H4CBD), and hexahydrocannabidivarin (H4CBDV) derivatives are disclosed. Also disclosed are pharmaceutical compositions comprising such derivatives. Further described are methods of use thereof for treatment and prevention of cancer, including pancreatic and lung cancer.

Disclosed is an aptamer capable of binding to Cannabielsoin (CBE), wherein the aptamer is: an RNA aptamer having a nucleotide sequence of: CGCGGGCAGUGNNNUGCANNNNNNNNUGUGNNNUAUUAGC (SEQ ID NO: 1); or a DNA aptamer having a nucleotide sequence of: CGCGGGCAGTGNNNTGCANNNNNNNNTGTGNNNTATTAGC (SEQ ID NO: 2), wherein for SEQ ID NO: 1, N is one nucleotide selected from the group consisting of A, G, U and C, and wherein for SEQ ID NO: 2, N is one nucleotide selected from the group consisting of A, G, C and T. Also disclosed is a riboswitch and a DNA expression cassette comprising the aptamer, a composition thereof, and a microbe containing the riboswitch or DNA expression cassette. Further disclosed is a method of detecting CBE produced in a microbe using the aptamer or riboswitch as disclosed herein.

To provide enzymes and methods for synthesizing cannabinoids with specificity and a high yield.SOLUTION: Provided herein is a method for generating one or more cannabinoids, comprising a step of contacting cannabigerolic acid to a cannabinoid synthase ortholog. The cannabinoid synthase ortholog derives from organisms other than Cannabis sativa. Also disclosed is a recombinant cell of Saccharomyces cerevisiae or Pichia pastoris comprising a nucleic acid encoding the cannabinoid synthase ortholog in the genome. The cannabinoid synthase ortholog is expressed in the recombinant cell in an active form.SELECTED DRAWING: Figure 1

Compositions of cannabinoid and kinase inhibitors are useful for the treatment of hepatocellular carcinoma (HCC). Comprising cannabinolic acid (CBNA) and sorafenib synergistically acts on HepG2 cells, an in vitro liver cancer model and an in vitro human xenograft (PDX) HCC model. All of the disclosed compositions have superior effects than sorafenib used alone, while sorafenib is a first and second line chemotherapeutic agent selected for the treatment of HCC.